ABSTRACT
A potential protective role of vitamin D serum levels on overall adverse outcomes of SARS-CoV-2 infection or COVID-19 on populations had been suggested previously based upon single-point cross-sectional analysis of 8 April 2020 data from 20 European countries assuming comparable underlying confounding variables for these populations, at an early stage of the current pandemic. Comparative time-series cross-sectional analysis of the COVID-19 data from 12 March (early pre-peak) to 26 July (late post-peak of infections) 2020 was performed to assess the strength of the assertion. The study subjects included 1,829,634 COVID-19 cases (11.11% of total worldwide) and 179,135 associated deaths (27.45 % of total worldwide) on 26 July 2012. Previously suggested cross-sectional study design and methodology could not consistently and significantly (p-value≥0.05) support the notion of the potential protective role of the mean serum vitamin D levels of the populations on COVID-19 incidence and mortality. However, the exponential correlative model, as well as alternative simple regression analysis on ln and Log10 transformed COVID-19 data for the time period indicated improved consistently negative covariation with vitamin D levels. Additionally, the later methodology increased the predictive potential for explaining the variability in data [R2 by 1.27-1.96 fold, adjusted-R2 by 1.33-2.47, p-value=0.0457-0.0035, for cases/million; R2 by 1.81-2.67, adjusted-R2 by 2.21-3.74 fold for deaths/million, p-value=0.0049-0.0228). Considering, the established role of vitamin D in immune system functioning randomized well-controlled trials may be suggested to evaluate/assess the potential protective role of vitamin D in reducing the COVID-19 impact on populations.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding for the current work was received from any agency.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
NA
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos